We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
““Despite class 1 guideline recommendations and randomized controlled trials demonstrating mortality benefit, along with being a generic, affordable medication, MRA continues to be markedly underutilized in HFrEF,” write authors Amrita Mukhopadhyay, MD, FACC, et al. “Our findings demonstrated the potential for a relatively low cost, scalable solution to broadly improve prescribing of MRA across multiple institutions.””
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Mukhopadhyay et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: